Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone
暂无分享,去创建一个
[1] P. Moraitis,et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study , 2009, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[2] G. D’Amico,et al. Long‐term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial , 2009, British journal of haematology.
[3] M. Cappellini,et al. Guidelines for the Clinical Management of Thalassaemia , 2008 .
[4] G. Spanos,et al. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with β-thalassemia major , 2007 .
[5] E. Vichinsky,et al. Phase Ib clinical trial of starch‐conjugated deferoxamine (40SD02): a novel long‐acting iron chelator , 2007, British journal of haematology.
[6] D. Pennell,et al. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.
[7] A. Christoforidis,et al. Four‐year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β‐thalassaemia major: comparison between different chelation regimens , 2007, European journal of haematology.
[8] G. Spanos,et al. comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major. , 2007, International journal of hematology.
[9] M. Cappellini,et al. Thalassemia intermedia: revisited. , 2006, Blood cells, molecules & diseases.
[10] Mark A Westwood,et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. , 2006, Blood.
[11] A. Cnaan,et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. , 2006, Blood.
[12] A. Cohen,et al. New advances in iron chelation therapy. , 2006, Hematology. American Society of Hematology. Education Program.
[13] E. Alexopoulou,et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. , 2006, Blood cells, molecules & diseases.
[14] D. Pennell,et al. A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy with Deferoxamine and Deferiprone on Myocardial Iron in Thalassaemia Major Using Cardiovascular Magnetic Resonance. , 2005 .
[15] Z. Cabantchik,et al. LPI-labile plasma iron in iron overload. , 2005, Best practice & research. Clinical haematology.
[16] D. Pennell,et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.
[17] G. Kontoghiorghes,et al. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. , 2004, Current medicinal chemistry.
[18] P. Jarritt,et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. , 2004, Blood.
[19] E. Neufeld,et al. Complications of beta-thalassemia major in North America. , 2004, Blood.
[20] G. Sanna,et al. Iron overload and desferrioxamine chelation therapy in β-thalassemia intermedia , 1981, European Journal of Pediatrics.
[21] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[22] R. Galanello,et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. , 2003, Blood.
[23] A. Hoffbrand,et al. Clinical trial of deferiprone iron chelation therapy in β‐thalassaemia/haemoglobin E patients in Thailand , 2003, British journal of haematology.
[24] A. Hoffbrand,et al. Role of deferiprone in chelation therapy for transfusional iron overload. , 2003, Blood.
[25] A. Hoffbrand,et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients , 2003, British journal of haematology.
[26] A. Piga,et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. , 2003, Haematologica.
[27] D. Pennell,et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.
[28] G. D’Amico,et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. , 2002, Blood cells, molecules & diseases.
[29] Matthew Darlison,et al. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.
[30] J. Porter,et al. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia , 2000 .
[31] J. Porter,et al. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. , 2000, Blood.
[32] N. Olivieri. The β-Thalassemias , 1999 .
[33] Wright,et al. Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.
[34] K. Fleming,et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.
[35] M. Cappellini,et al. Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.
[36] G. Brittenham,et al. Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.
[37] C. Borgna-Pignatti,et al. Evaluation of a new method of administration of the iron chelating agent deferoxamine. , 1997, The Journal of pediatrics.
[38] A. Piga,et al. Results of long-term iron-chelating therapy. , 1996, Acta haematologica.
[39] G. Kontoghiorghes. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. , 1995, Toxicology letters.
[40] G. Koren,et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.
[41] G. Kontoghiorghes. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. , 1995, The Analyst.
[42] A. Bartlett,et al. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. , 1995, Arzneimittel-Forschung.
[43] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[44] G. Koren,et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. , 1994, Blood.
[45] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[46] R. Abeysinghe,et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[47] R. Puniyani,et al. Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial , 1992, British journal of haematology.
[48] I. Adamson,et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning , 1992, The Lancet.
[49] G. Koren,et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. , 1992, Blood.
[50] G. Koren,et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients , 1990, The Lancet.
[51] A. Hoffbrand,et al. Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIES , 1990, British journal of haematology.
[52] G. Kontoghiorghes,et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one , 1990, Clinical pharmacology and therapeutics.
[53] K. Konstantopoulos,et al. Acute Bone Marrow Aplasia Associated with Intravenous Administration of Deferoxamine (Desferrioxamine) , 1990, Drug safety.
[54] D. Weatherall,et al. Iron balance and the management of iron overload in beta-thalassemia intermedia. , 1988, Birth defects original article series.
[55] S. Underwood,et al. DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJOR , 1984, The Lancet.
[56] S. De Virgiliis,et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. , 1981, European journal of pediatrics.
[57] A. Marty,et al. Recovery from non-traumatic localised gas gangrene and clostridial septicaemia. , 1969, Lancet.
[58] H. Keberle. The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism , 1964, Annals of the New York Academy of Sciences.